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Purpose: Gender differences in the incidence, susceptibility and severity of many obstruc-
tive airway diseases (OADs) have been well recognized. However, gender differences in the 
inhaled pharmacotherapy profile are not well characterized.
Methods: We conducted a retrospective cohort study to investigate gender differences in 
new-users of inhaled corticosteroids (ICS), short-or long-acting beta2-agonist (SABA or 
LABA), ICS/LABA, short-or long-acting muscarinic antagonist (SAMA or LAMA) among 
patients with asthma, COPD or asthma-COPD overlap (ACO). We used Clinical Practice 
Research Datalink to identify OAD patients, 18 years and older, who were new-users (1-year 
washout period) from 01-January-1998 to 31-July-2018. Multivariable logistic regression 
was used to examine gender differences in each of the inhaled pharmacotherapies after 
controlling for potential confounders.
Results: A total of 242,079 new-users (asthma: 84.93%; COPD: 10.19%; ACO: 4.88%) of 
inhaled pharmacotherapies were identified. The multivariable analyses showed that males 
with COPD were more likely to be a new user of a LABA (odds ratio [OR] 1.29; 95% 
confidence interval [CI], 1.12–1.49), LAMA (OR 1.21; 95% CI 1.10–1.33), SAMA (OR 
1.11; 95% CI 1.01–1.21) and less likely to be a new user of a SABA (OR 0.84; 95% CI, 
0.80–0.89) compared to females. Similar patterns were also observed for patients with ACO; 
males were more likely to be prescribed with LABA (OR 1.26; 95% CI 1.03–1.55), LAMA 
(OR 1.28; 95% CI 1.11–1.48), SAMA (OR 1.28; 95% CI 1.11–1.48), and less likely to be 
a new user of a SABA (OR 0.89; 95% CI, 0.82–0.96). Also, males with asthma were more 
likely to be a new-user of ICS/LABA (OR 1.15; 95% CI, 1.08–1.23) and less likely to start 
an ICS (OR 0.97; 95% CI, 0.95–0.99) in comparison with females.
Conclusion: Our study showed significant gender differences in new-users of inhaled 
pharmacotherapies among OAD patients. Adjusting for proxies of disease severity, 
calendar year, smoking and socioeconomic status did not change the association by gender.
Keywords: inhaled pharmacotherapies, asthma, COPD, asthma-COPD overlap, gender, drug 
utilization
Introduction
Asthma and chronic obstructive pulmonary disease (COPD) are the two most 
common categories of respiratory diseases characterized by airway obstruction.1,2 
Recently a new phenotype, referred to as asthma-COPD overlap (ACO), has been 
identified with its first guidelines for treatment and management in effect since 
2015.3 Gender differences exist in most common health conditions and especially in 
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lung diseases such as asthma and COPD.4 These assertions 
have been evident by many studies showing significant 
differences in medical treatments between females and 
males with the same respiratory condition such as asthma 
and COPD.5–7 Although the mechanisms of gender differ-
ences are not fully understood, many population studies 
and cluster analyses have shown that gender, race, envir-
onment, genetics and specific phenotypes have played 
important roles in asthma symptoms and management.8–10
The airflow obstruction in patients with obstructive 
airway diseases (OADs) is either fixed or reversible by 
medication.11 The clinical guidelines for asthma, COPD 
and asthma-COPD overlap convey equal treatment 
between males and females.1 For patients with asthma, 
the Global Initiative for Asthma (GINA) guideline recom-
mends treating everyone with combination therapy of 
inhaled corticosteroid/long-acting beta2-agonist (ICS/ 
LABA) on an as-needed basis, even for mild patients 
(GINA step 1 and step 2).1
The clinical guideline for COPD proposes building up 
treatment from short-acting beta2-agonist (SABA) to sin-
gle LABA or long-acting muscarinic antagonist (LAMA) 
to combination therapy of LABA/LAMA, then step-up to 
ICS/LABA/LAMA triple therapy in those with frequent 
acute exacerbation chronic obstructive pulmonary disease 
(AECOPD) or persistent symptoms; whist the asthma- 
COPD overlap guideline advocates treatment with asthma 
medication and to continue steadily with COPD medica-
tions as the disease progresses to lessen the risk of 
exacerbations.2 Furtherance to this suggestion, a recent 
systematic review concluded that patients with asthma- 
COPD overlap may benefit from combination therapy of 
inhaled corticosteroids/long-acting beta2-agonist (ICS/ 
LABA) combination therapy which appears to reduce the 
risk of death or hospitalization.12
Over the years, gender-specific epidemiological studies 
and clinical trials have been lacking in detailing differ-
ences in pharmacotherapy utilization in patients with 
obstructive airways diseases which may have important 
implications in symptoms and disease management.13,14 
However, this phenomenon has long been established in 
cardiovascular disease and is labelled as Yentl syndrome 
stating female receive generally less treatment (across the 
spectrum of medical and interventional therapy) for 
ischaemic heart disease than their male equivalents.15,16
Whilst it is evident that recommendations for treatment 
with inhaled pharmacotherapy for asthma, COPD and 
asthma-COPD overlap have changed tremendously over 
several decades, gender differences in inhaled pharma-
cotherapy of asthma, COPD and asthma-COPD overlap 
in both randomized control trials and observational studies 
have not been demonstrated before. Therefore, we sought 
to investigate gender differences in new-users of ICS 
monotherapy, ICS/LABA combination therapy, LABA 
monotherapy, LAMA monotherapy, SABA monotherapy 
and short-acting muscarinic antagonist (SAMA) mono-




We conducted a retrospective observational cohort study 
using primary care records from CPRD. The CPRD is 
a United Kingdom (UK) based database which is repre-
sentative of UK population that contains de-identified, 
longitudinal data, with approximately 700 total contribut-
ing general practitioner (GP) primary care practices and 
more than 14 million acceptable (good quality) patients.17 
Patients’ data are available for demographics, symptoms 
and diagnoses, primary care prescriptions, test results, 
referrals to specialist and lifestyle information (smoking, 
alcohol). Approximately half of the source population 
(study population) is linked to hospital records (Hospital 
Episode Stats, HES) and death certificate (Office of 
National Statistics, ONS).18 Our study was conducted in 
compliance with the ethical principles of the Declaration 
of Helsinki, International Council for Harmonisation Good 
Clinical Practice (GCP) and received approval from the 
Health Research Ethics Board at Memorial University. The 
study protocol was approved by the CPRD Independent 
Scientific Advisory Committee (ISAC 18_005RA). 
Generic ethical approval for observational research using 
the CPRD with approval from ISAC has been granted by 
a Health Research Authority (HRA) Research Ethics 
Committee. Patient informed consent was not necessary 
since the data were anonymized for research purposes.
Study Population and Identification of 
Inhaled Pharmacotherapies
The study population included patients who were registered 
with up-to-standard practice and active between January 1, 
1998 and July 31, 2018 inclusive (Figure 1). This population 
comprised male and female patients in CPRD database with an 
incident read code (see supplementary file) for asthma and/or 
COPD defined as at least one diagnostic record for either 
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disease and a new-user of ICS, SABA, LABA, combination 
therapy of ICS/LABA, SAMA or LAMA (see supplementary 
file). Patients with asthma-COPD overlap were defined as 
having; 1) COPD read code and 2) asthma read code and 3) 
an ex or current smoker (if never smoked, exposure to wood 
smoke, biofuels, randon gas or second-hand smoke) before the 
index date (the date of first prescription of inhaled 
pharmacotherapy). To identify new-users of inhaled pharma-
cotherapy, patients with a record of taking any inhaler drug 
within 365 days before their first medication prescription were 
excluded. Recent validation studies in the CPRD GOLD data-
base have shown that patients with asthma or COPD can be 
accurately identified from CPRD database using specific diag-
nostic codes.19,20
Figure 1 Flowchart of study cohort formation. 
Abbreviations: CPRD, Clinical Practice Research Datalink; OADs, obstructive airway diseases; COPD, chronic obstructive pulmonary disease; ACO, asthma-COPD 
overlap; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting beta agonist; SAMA, short-acting 
muscarinic antagonist; Rx, prescription.
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Exposure and Outcomes
The primary exposure variable of interest was gender 
which was defined as either male or female based on 
medical records from the patient’s general practitioner. 
The outcomes of interests were new-users of the following 
mutually exclusive categories of inhaled 
pharmacotherapies:
1. ICS monotherapy (budesonide, fluticasone, mome-
tasone, beclomethasone, ciclesonide and 
flunisolide);
2. ICS/LABA combination therapy (fluticasone propio-
nate/formoterol fumarate, Budesonide/formoterol 
fumarate, beclomethasone dipropionate/formoterol 
fumarate, fluticasone furoate/vilanterol, fluticasone 
propionate/salmeterol xinafoate, budesonide/formo-
terol fumarate and mometasone furoate/formoterol 
fumarate);
3. LABA monotherapy (salmeterol xinafoate, indaca-
terol maleate, olodaterol, vilanterol and formoterol 
fumarate);
4. LAMA monotherapy (tiotropium bromide, aclidi-
nium bromide and umeclidinium bromide);
5. SABA monotherapy (salbutamol, terbutaline sulfate, 
fenoterol hydrobromide, rimiterol, pirbuterol, repro-
terol and orciprenaline sulfate); or
6. SAMA monotherapy (ipratropium bromide and oxi-
tropium bromide).
New-users were defined using a 1-year washout period 
whereby no prescription for any agent in the aforemen-
tioned categories was recorded in the previous 365 days. 
We considered only the first treatment; therefore, any sub-
sequent switches, discontinuations or new therapies were 
not examined in our analysis. Since recommendations on 
inhaled pharmacotherapy for patients with obstructive lung 
diseases may have changed over the years, we also con-
sidered calendar year in our analysis; 1. First decade 
spanning January 1, 1998 to December 31, 2007 and 2. 
Second decade spanning January 1, 2008 to July 31, 2018.
Statistical Analysis
Descriptive statistics for asthma, COPD and asthma- 
COPD overlap including count/percentage and mean/stan-
dard deviation were provided for categorical and contin-
uous variables, respectively. For categorical variables with 
more than two categories, type 3 p-values (a p-value 
indicating the overall effect of all levels of a categorical 
variable) were also calculated. An interaction term 
between gender and a variable indicating OAD types 
(asthma, COPD or asthma-COPD overlap) was introduced 
into multivariable models to examine the association 
between gender and a pharmacotherapy for patients with 
asthma, COPD and asthma-COPD overlap, respectively. 
The initial multivariable model included clinical important 
variables and all variables which were significant at 
p=0.20 in the univariate analysis. Then we started by 
removing the least significant variable one at a time, 
until all the variables in the final multivariable model are 
either clinically important or significant at p=0.05. The 
strength of an association was measured as an Odds 
Ratio (OR), 95% Confidence Interval (95% CI). Data 
analysis was conducted using SAS (version 9.4, SAS 
Institute Inc.) on IBM cluster.
Results
We identified a total number of 242,079 new-users of 
inhaled pharmacotherapies of which 85% had asthma, 
10% had COPD and 5% had asthma-COPD overlap. 
Among them, around 67% were identified in the first 
decade (January 1, 1998–December 31, 2007) and around 
34% were identified in the second decade (January 1, 
2008–July 31, 2018). The average age of our study popu-
lation was 52 (±22) years, 113,712 (47%) were females 
and 128,367 (53%) were males. Table 1 summarizes the 
characteristics of patients with obstructive airway diseases. 
In relation to other respiratory drugs received before 
cohort entry, more than 28,000 patients received oral cor-
ticosteroids with very few patients receiving methyl-
xanthine (0.5%).
Table 2 shows results from the univariate analyses of 
factors associated with different inhaled pharmacothera-
pies. Increasing age was significantly associated with 
increased prescription of all inhaled pharmacotherapies, 
except ICS and SABA prescriptions. In comparison to 
females, males were significantly associated with 
increased prescriptions of ICS/LABA, LABA, LAMA 
and SAMA, and with decreased prescriptions of ICS, and 
SABA. In comparison to patients entering cohort between 
January 1998–December 2007, those entering cohort 
between January 2008–July 2018 showed significantly 
higher rates of ICS, LABA and SAMA, and significantly 
lower rates of ICS/LABA, LAMA, and SABA. Other 
variables which were significantly associated with the six 
inhaled pharmacotherapies included body mass index 
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Age (mean, STD) 46.86 (±19.6) 79.38 (±12.6) 76.08 (±15.9) 51.60 (±22.0)
Gender
Male 92,849 (45.2%) 14,350 (58.2%) 6,513 (55.1%) 128,367 (53%)
Female 112,747 (54.8%) 10,322 (41.8%) 5,298 (44.9%) 113,712 (47%)
Year of cohort entry
January 1998–December 2007 143,333 (69.7%) 11,210 (45.4%) 6,417 (54.3%) 160,960 (66.5%)
January 2008–July 2018 62,263 (30.3%) 13,462 (54.6%) 5,394 (45.7%) 81,119 (33.5%)
Body mass index (BMI)
Underweight 16,841 (11.2%) 1,251 (5.6%) 479 (4.4%) 18,571 (10.2%)
Normal 59,896 (40.0%) 8,751 (39.5%) 3,885 (36.1%) 72,532 (39.7%)
Overweight 42,006 (28.0%) 7,101 (32.0%) 3,755 (34.9%) 52,862 (28.9%)
Obese 31,086 (20.8%) 5070 (22.9%) 2654 (24.6%) 38,810 (21.2%)
Rx received as initial treatment
ICS 71,024 (34.6%) 3245 (13.2%) 2869 (24.3%) 77,138 (31.9%)
ICS/LABA 3737 (1.8%) 2084 (8.5%) 1017 (8.6%) 6838 (2.8%)
LABA 1253 (0.6%) 875 (0.4%) 410 (3.4%) 2538 (1.1%)
LAMA 97 (0.1%) 2436 (9.9%) 538 (4.7%) 3071 (1.3%)
SABA 128,379 (62.4%) 13,609 (55.2%) 6069 (51.4%) 148,057 (61.1%)
SAMA 1106 (0.5%) 2423 (9.8%) 908 (7.6%) 4437 (1.8%)
Index of deprivation
Least deprived 46,363 (22.6%) 3760 (15.3%) 1873 (15.9%) 51,996 (21.5%)
Less deprived 43,752 (21.3%) 4673 (19.0%) 2292 (19.4%) 50,717 (21.0%)
Deprived 42,186 (20.5%) 4915 (16.0%) 2320 (19.7%) 49,421 (20.4%)
More deprived 38,377 (18.7%) 5257 (21.3%) 2606 (22.1%) 46,240 (19.1%)
Most deprived 34,681 (16.9%) 6026 (24.4%) 2714 (22.9%) 43,421 (18.0%)
Smoking status
No 89,199 (56.4%) 2493 (10.4%) 2199 (19.1%) 93,891 (48.5%)
Yes 38,991 (24.6%) 11,214 (46.8%) 4220 (36.6%) 54,425 (28.1%)
Ex-smoker 29,998 (19.0%) 10,246 (42.8%) 5112 (44.3%) 45,356 (23.4%)
Respiratory drugs before cohort entry
Oral corticosteroid
Yes 21,803 (10.6%) 4562 (18.5%) 2446 (20.7%) 28,811 (11.9%)
No 183,793 (89.4%) 20,110 (81.5%) 9365 (79.3%) 213,268 (88.1%)
Methylxanthine
Yes 574 (0.3%) 331 (1.3%) 241 (2.0%) 1146 (0.5%)
No 205,022 (99.7%) 24,341 (98.7%) 11,570 (98.0%) 240,933 (99.5%)
Other drugs before cohort entry
NSAIDs
Yes 24,211 (11.8%) 3771 (15.3%) 1798 (15.2%) 29,780 (12.3%)
No 181,385 (88.2%) 20,901 (84.7%) 10,013 (84.8%) 212,299 (87.7%)
Opioids
Yes 6219 (3.0%) 2429 (9.9%) 1025 (8.7%) 9673 (4.0%)
No 199,377 (97.0%) 22,243 (90.1%) 10,786 (91.3%) 232,406 (96.0%)
Acetaminophen
Yes 12,782 (6.2%) 4245 (17.2%) 1637 (13.9%) 18,664 (7.7%)
(Continued)
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(BMI), index of deprivation, smoking status, other drugs 
(NSAID, opioids, Acetaminophen), comorbidity, and sev-
eral disease severity indicators (prescription of methyl-
xanthine, oral corticosteroid and number of 
hospitalization). However, prescription of ICS/LABA was 
not significantly associated with Index of deprivation.
Table 3 shows adjusted results from multivariable analysis 
after controlling for all potential confounders in Table 2. 
Among the patients diagnosed with asthma, male patients 
were significantly less likely to be a new-user of ICS mono-
therapy (adjusted OR 0.97; 95% CI 0.95–0.99, p=0.01) and 
more likely to be prescribed ICS/LABA combination therapy 
(adjusted OR 1.15; 95% CI 1.08–1.23, p<0.0001) than female 
patients. Among patients with COPD, males were more likely 
to be prescribed a LABA (adjusted OR 1.29; 95% CI 1.12–-
1.49, p=0.0005), LAMA (adjusted OR 1.21; 95% CI, 1.10–-
1.33, p<0.0001), and SAMA (adjusted OR 1.11; 95% CI, 
1.01–1.21, p=0.02) and significantly less likely to be pre-
scribed a SABA (adjusted OR 0.84; 95% CI, 0.80–0.89, 
p<0.0001) than female patients. Similar associations were 
also observed among patients diagnosed with ACO, in which 
male patients had significantly higher rates in initial prescrip-
tion of LABA (adjusted OR 1.26; 95% CI, 1.03–1.55, p=0.03), 
LAMA (adjusted OR 1.27; 95% CI, 1.05–1.53, p=0.01) and 
SAMA (adjusted OR 1.28; 95% CI, 1.11–1.48, p=0.0008) and 
significantly lower rate in SABA (adjusted OR 0.89, 95% CI, 
0.82–0.96, p=0.003) than female patients.
Discussion
Using a large population-based cohort of asthma, COPD 
and asthma-COPD overlap patients from a period of 
January 1, 1998 to July 31, 2018, we found significant 
differences in inhaled pharmacotherapies between females 
and males among patients with obstructive airway dis-
eases. Adjusted multivariable analyses showed males in 
comparison to females with COPD or asthma-COPD over-
lap were more likely to be a new user of a LABA, LAMA, 
and SAMA and less likely to be a new user of a SABA. 
Also, males with asthma were more likely to be a new- 
user of ICS/LABA and less likely to start an ICS.
There are several medications that are currently available 
for the treatment of asthma but no differential preferences 
between females and males have been suggested in clinical 
practice guidelines of asthma and COPD globally.1,2 The 
GINA guideline recommends that all or most asthma patients 
should have an ICS therapy in their regimen. In COPD how-
ever, the treatment option is to avoid ICS if possible as 
increased use of ICS alone increases the risk of pneumonia 
in these patients.21,22 Noticeably, among patients with asthma, 
female patients have a significant, albeit small, increase of 
ICS monotherapy use as initial treatment in comparison with 
the males in our study. Although the exact reasons for this 
observed gender differences are not fully understood, the 
significant increase use of ICS monotherapy among female 
patients with asthma could be partially explained by more 









No 192,814 (93.8%) 20,427 (82.8%) 10,0174 (85.1%) 223,415 (92.3%)
Comorbidity in year before cohort entry
0 164,782 (80.2%) 7771 (31.5%) 4569 (38.7%) 177,122 (73.2%)
1 26,980 (13.1%) 7332 (29.7%) 3403 (28.8%) 37,715 (15.6%)
>1 13,834 (6.7%) 9569 (38.8%) 3839 (32.5%) 27,242 (11.2%)
Physician visits in year before cohort entry
1–17 184,396 (89.7%) 16,077 (65.2%) 8270 (70.0%) 208,743 (86.2%)
18–35 18,440 (9.0%) 6,885 (27.9%) 2896 (24.5%) 28,221 (11.7%)
>36 2760 (1.3%) 1710 (6.9%) 645 (5.5%) 5115 (2.1%)
No. of hospitalization in year before cohort entry
0 176,156 (85.7%) 16,226 (65.8%) 8643 (73.2%) 201,025 (83.0%)
1 20,662 (10.1%) 5027 (20.4%) 1939 (16.4%) 27,628 (11.4%)
>1 8778 (4.2%) 3419 (13.8%) 1229 (10.4%) 13,426 (5.6%)
Abbreviations: ICS, inhaled corticosteroid; SABA, short-acting beta2-agonist; LABA, long-acting beta2-agonist; SAMA, short-acting muscarinic antagonist; LAMA, long- 
acting muscarinic antagonist; LAMA, long-acting muscarinic antagonist; COPD, chronic obstructive pulmonary disease; CI, confidence interval; ACO, asthma-COPD overlap; 
Rx, prescription; STD, standard deviation; NSAIDs, nonsteroidal anti-inflammatory drugs.
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frequent reports of asthma symptoms in female patients than 
males. In the American Lung Association Asthma Clinical 
Research Centers (ALA-ACRC) trials to determine if sex 
differences in asthma control or symptom profiles exist, they 
observed that females were more likely to report specific 
symptoms such as nocturnal awakenings, activity limitations, 
and shortness of breath compared to males.23
In contrast to ICS monotherapy initiation, males with 
asthma received more ICS/LABA as first-line therapy 
compared to females. It is plausible that male asthmatics 
were being treated aggressively compared to females as 
the former were more likely to receive more step-up treat-
ment or superior treatment than the later. It is also inter-
esting that whilst it is known that females have a worse 
perception of asthma, feel it as more symptomatic and 
suffer a greater impact on their quality of life (QoL), our 
findings demonstrated they are less likely to receive ICS/ 
LABA than their male counterparts initially.24 
Nevertheless, we found no gender difference in either 
COPD or asthma-COPD overlap patients prescribed ICS 
monotherapy, or the combination therapy of ICS/LABA.
The observed gender differences could be partially 
explained that the average physician recognizes symptoms 
in males and respond to them more aggressively than they 
would have done to females with either COPD alone or 
asthma-COPD overlap. In an observational study to objec-
tively measure and compare reported sleep disturbances due 
to symptoms in males and females, the authors reported that 
sleep disturbances were significantly more prevalent in 
males with COPD compared with controls; whereas there 
was no significant difference in females.25 Indeed, it is 
perceived that COPD is seen as male-dominated disease.26 
Alternatively, gender differences may be partially explained 
by differences in disease characteristics. Papaioannou et al 
found that female patients were characterized by milder 
forms of COPD disease relative to males, and comorbidities 
were more prevalent in males than in females.27 As such, it 
is possible that females presenting with COPD were being 
treated more with asthma medications. Yet, the COPD 
GOLD clinical guideline reports no differential treatment 
between genders.2
We observed similar differences among patients with 
asthma, COPD and asthma-COPD overlap in our study 
who were new-users of rescue medications. Female 
patients with either COPD or asthma-COPD overlap 
were more like to receive SABA compared to males. 
This is consistent with Dunn et al study which found 
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pharmacotherapy in females vs males (36.2% vs 13.1%; 
p=0.051).28 Even though we found that males were less 
likely to receive rescue medication of SABA, on aver-
age, they were on more superior therapy (SAMA) com-
pared to females. This observation may be due to the fact 
that common respiratory infections in COPD are respon-
sible for most of the incidents of worsened COPD.29 
Furthermore, males are more susceptible to bacteria 
and virus infections, infectious complications after sur-
gery, severe sepsis and septic shock.30–33
This study has strengths and limitations. A major 
strength of our study is the size of our study population 
which consists of more than 240,000 patients. Another 
strength is the quality of our cohort and its robust capture 
of medication data. The CPRD is a high-quality database 
which is representative of approximately 14 million accep-
table patients. This attribute makes the study representa-
tive of the overall United Kingdom population of 
obstructive airway patients diagnosed with asthma, 
COPD and asthma-COPD overlap.
Among limitations is the potential for medication 
misclassification as the CPRD database does not cap-
ture prescriptions from specialists or prescriptions 
given in a hospital setting. Given most of these agents 
would be initially prescribed or continued by GPs, the 
degree of misclassification is likely very low. Another 
limitation of this study is the lack of information on 
lung function tests such as FEV1 and FEV1/FVC ratio 
due to large missing values or its unavailability in 
entirety even though we adjusted for multiple impor-
tant disease severity indicators such as age, body mass 
index, material deprivation, smoking status, comorbid-
ities, oral corticosteroid use (indicator for exacerba-
tion), number of hospitalizations, GPs’ visits and 
treatment (comedications). Finally, on the validity of 
the asthma-COPD overlap subgroup. Just as the clinical 
definition of asthma or COPD is still debatable, as 
things stand, there is not a standard definition for 
patients with asthma-COPD overlap. However, we 
defined these patients as having; 1) COPD read code 
and 2) asthma read code and 3) an ex or current 
smoker (if never smoked, exposure to wood smoke, 
biofuels, randon gas or second-hand smoke) before 
the index date. The read codes for both asthma and 
COPD in the CPRD have been extensively validated 
and used in several studies.
Table 3 Multivariable Analyses of Gender Differences in Inhaled Pharmacotherapies by Three Obstructive Airway Diseases
Pharmacotherapies# Asthma COPD Asthma-COPD Overlap
OR: 95% CI (aOR: 95% CI) OR: 95% CI aOR: 95% CI OR: 95% CI aOR: 95% CI
ICS
Female 1 1 1 1 1 1
Male 1.03 (1.01–1.05)* 0.97 (0.95–0.99)* 0.99 (0.92–1.07) 0.98 (0.90–1.07) 0.89 (0.82–0.97)* 0.91 (0.83–1.00)
ICS/LABA
Female 1 1 1 1 1 1
Male 0.98 (0.92–1.05) 1.15 (1.08–1.23)** 1.07 (0.98–1.17) 1.06 (0.97–1.18) 1.11 (0.97–1.26) 1.09 (0.96–1.25)
LABA
Female 1 1 1 1 1 1
Male 0.94 (0.83–1.05) 1.04 (0.92–1.18) 1.27 (1.10–1.46)* 1.29 (1.12–1.49)* 1.23 (1.01–1.50)* 1.26 (1.03–1.55)*
LAMA
Female 1 1 1 1 1 1
Male 1.14 (0.77–1.70) 1.40 (0.93–2.10) 1.20 (1.11–1.31)** 1.21 (1.10–1.33)** 1.33 (1.11–1.59)* 1.27 (1.05–1.53)*
SABA
Female 1 1 1 1 1 1
Male 0.97 (0.95–0.99)* 1.00 (0.98–1.02) 0.87 (0.83–0.91)** 0.84 (0.80–0.89)** 0.93 (0.86–0.99)* 0.89 (0.82–0.96)*
SAMA
Female 1 1 1 1 1 1
Male 1.12 (0.99–1.26) 1.13 (0.98–1.30) 1.08 (0.99–1.17) 1.11 (1.01–1.21)* 1.22 (1.06–1.40)* 1.28 (1.11–1.48)*
Notes: **p < 0.0001; *p < 0.05; #Adjusted for all factors listed in Table 2. 
Abbreviations: OR, unadjusted odds ratio; aOR, adjusted odds ratio; ICS, inhaled corticosteroid; SABA, short-acting beta2-agonist; LABA, long-acting beta2-agonist; 
SAMA, short-acting muscarinic antagonist; LAMA, long-acting muscarinic antagonist; COPD, chronic obstructive pulmonary disease; CI, confidence interval; ACO, asthma- 
COPD overlap.
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Conclusion
Albeit in a more specific population, our findings are 
consistent with van der Verde et al whom found that over-
all prescription rates were substantially higher in females 
than in males with diverse regional and ethnic differences 
and called for renewed efforts to close expanding gender 
treatment gap.34 Our findings are novel and highlights GPs 
potential unconscious bias in management of obstructive 
airway disease patients. In conclusion, we observed an 
overall gender difference in first time drug use to treat 
patients with asthma, COPD or asthma-COPD overlap 
who are new-users of inhaled pharmacotherapies from 
January-01, 1998 to July-31, 2018. Adjusting for proxies 
of disease severity, smoking and socioeconomic (material 
deprivation) status did not change the association by 
gender.
Abbreviations
OAD, obstructive airway disease; ICS, inhaled corticos-
teroid; SABA, short-acting beta2-agonist; LABA, long- 
acting beta2-agonist; SAMA, short-acting muscarinic 
antagonist; LAMA, long-acting muscarinic antagonist; 
LAMA, long-acting muscarinic antagonist; COPD, 
chronic obstructive pulmonary disease; CI, confidence 
interval; ACO, asthma-COPD overlap; Rx, prescription; 
STD, standard deviation; NSAIDs, nonsteroidal anti- 
inflammatory drugs; CPRD, Clinical Practice Research 
Datalink.
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